Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows:—D (v,0.1) is between 10 and 30 micrometers,—D (v,0.5) is between 30 and 70 micrometers,—D(v,0.9) is between 50 and 110 micrometers.

Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: —D (v,0.1) is between 10 and 30 micrometers, —D (v,0.5) is between 30 and 70 micrometers, —D(v,0.9) is between 50 and 1 10 micrometers.

Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: —D (v,0.1) is between 10 and 30 micrometers, —D (v,0.5) is between 30 and 70 micrometers, —D (v,0.9) is between 50 and 1 10 micrometers.

Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: D (v,0.1) is between 10 and 30 micrometers, D (v,0.5) is between 30 and 70 micrometers, D (v,0.9) is between 50 and 1 10 micrometers.

Abstract: Device for continuously producing particles, consisting of a homogenising compartment (1) including at least one inlet (2) for feeding in an organic phase, an inlet (3) for feeding in an aqueous phase, a mixing system (4) and an outlet (5).

Abstract: The present invention relates to a subcutaneous delivery system comprising a biodegradable polymeric matrix and at least one of the pharmacologically active substances of general formula (I): wherein A represents an amino group —NH2 or an ammonium group —NH3+ or a residue of general formula (II): wherein each of X1 to X5 represents, independently, an hydrogen atom, a linear or branched C1 to C6 alkyl group, a linear or branched C1 to C6 alkyloxy group, a hydroxyl group —OH, an amino group —NH2, a primary or secondary C1 to C6 alkylamino group, a halogen atom, a nitro group —NO2; said substance being embedded into said matrix. It relates also to a process for its preparation and to its use for the preparation of a medicament.

Abstract: The present invention relates to compositions comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition. The compositions of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral density and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

Abstract: The invention concerns a device (1) for inserting implants (10) in the form of a cylinder of small diameter comprising gripping means (2), a trocar (3) fixed through its proximal end (4) to the gripping means (2), and a push-rod (5) mounted sliding through the trocar (3) and the gripping means (2). The invention is characterized in that the gripping means (2) include a rotating element (6) defining an axis of rotation (7) parallel to the axis of the trocar (8) and comprising a plurality of tubular elements (9) arranged around said axis of rotation (7) and mounted so as to be aligned successively with the trocar (3), each tubular element (9) being adapted to contain at least two implants (10) arranged one behind the other.

Abstract: The present intention relates to an implant for the controlled release of at least one pharmaceutically active principle comprising a core containing at least one active principle and a sheath surrounding said core, wherein said sheath is composed of at least one polymeric film applied around said core. It also relates to a process for the preparation of such an implant, characterised by the production of a core containing at least one active principle, preparation of at least one polymeric film, application of the polymeric film(s) around said core by juxtaposition and/or superposition thereof, and sterilisation of the implant thus obtained.

Abstract: Pharmaceutical composition for the controlled release of at least one water-insoluble active principle, containing a homopolymer of D,L-lactic acid or of L-lactic acid of low molecular weight combined with said active principle, wherein the molecular weight of the homopolymer of D,L-lactic acid is between approximately 2,000 and 6,000 daltons or the molecular weight of the homopolymer of L-lactic acid is about 4,000 daltons.

Abstract: A composition designed for the sustained and controlled release of medicamentous peptide substances having the formula (I):Ac-D-Nal-D-pClPhe-R.sup.3 -Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH.sub.2wherein R.sup.3 is D-Pal or D-Trp. The composition is obtained in the form of microspheres of a biodegradable polymeric material incorporating a water-insoluble salt of the peptide of formula (I).

Abstract: The process is aimed at providing a composition designed for the sustained and controlled release of medicamentous peptide substances, obtained in the form of microspheres of a biodegradable polymeric material incorporating said medicamentous substance.It consists in converting first a water-soluble peptide or peptide salt into a water-insoluble peptide, respectively peptide salt. The following steps include preparing an organic-aqueous emulsion and then extracting the organic solvent in an excess of aqueous medium.

Abstract: A pharmaceutical composition is prepared in the form of microparticles or of an implant comprising a biodegradable polymer selected from poly-1,4-butylene succinate, poly-2,3-butylene succinate, poly-1,4-butylene fumarate and poly-2,3-butylene succinate, incorporating as the active substance the pamoate, tannate, stearate or palmitate of a natural or of a synthetic peptide comprising 3 to 45 amino acids, such as LH-RH, somatostatin, GH-RH or calcitonin, or one of their synthetic analogues or homologues. The preparation comprises dry blending the ingredients in the form of powders, pre-compressing and preheating the mixture and then extruding the pre-compressed and pre-heated mixture. The product resulting from the extrusion step can then be comminuted and finally sieved.

Abstract: The ultracentrifugal disintegrator includes a device for cooling the annular zone (7), extending from the outer face (8) of the rotor (4) to the inner face (9) of the sieve (5), by feeding a gaseous coolant to the upper part of the zone (7), vertically with respect to the zone (7). Such a disintegrator is used for the cryocomminution of heat sensitive material.

Abstract: The pharmaceutical composition is intended in particular for the sustained and controlled release of an effective dose of a medicinal substance. It comprises, as a carrier for the medicinal substance, a biodegradable polymer or copolymer or a mixture of biodegradable polymers and/or copolymers derived from a dicarboxylic acid selected from the acids of the Krebs cycle, and from an aliphatic diol containing 4 carbon atoms or from cyclohexane-1,4-dimethanol.